Join
Live feed
·
PRReleasevia Quantisnow
CERo Therapeutics Holdings Inc. logo

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

ByQuantisnow·Wall Street's wire, on your screen.
CERO· CERo Therapeutics Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CERO (CERo Therapeutics Holdings Inc.) and more on Quantisnow.